Publication:
Long-Term Outcomes Among a Nationwide Cohort of Patients Using an Implantable Cardioverter-Defibrillator: UMBRELLA Study Final Results.

dc.contributor.authorBriongos-Figuero, Sem
dc.contributor.authorGarcía-Alberola, Arcadio
dc.contributor.authorRubio, Jerónimo
dc.contributor.authorSegura, José María
dc.contributor.authorRodríguez, Aníbal
dc.contributor.authorPeinado, Rafael
dc.contributor.authorAlzueta, Javier
dc.contributor.authorMartínez-Ferrer, José B
dc.contributor.authorViñolas, Xavier
dc.contributor.authorFernández de la Concha, Joaquín
dc.contributor.authorAnguera, Ignasi
dc.contributor.authorMartín, María
dc.contributor.authorCerdá, Laia
dc.contributor.authorPérez, Luisa
dc.contributor.authorUMBRELLA Investigators *
dc.date.accessioned2023-02-09T10:38:38Z
dc.date.available2023-02-09T10:38:38Z
dc.date.issued2020-12-25
dc.description.abstractBackground Large-scale studies describing modern populations using an implantable cardioverter-defibrillator (ICD) are lacking. We aimed to analyze the incidence of arrhythmia, device interventions, and mortality in a broad spectrum of real-world ICD patients with different heart disorders. Methods and Results The UMBRELLA study is a prospective, multicenter, nationwide study of contemporary patients using an ICD followed up by remote monitoring, with a blinded review of arrhythmic episodes. From November 2005 to November 2017, 4296 patients were followed up. After 46.6±27.3 months, 16 067 episodes of sustained ventricular arrhythmia occurred in 1344 patients (31.3%). Appropriate ICD therapy occurred in 27.3% of study population. Patients with ischemic cardiomyopathy (hazard ratio [HR], 1.51; 95% CI, 1.29-1.78), dilated cardiomyopathy (HR, 1.28; 95% CI, 1.07-1.53), and valvular heart disease (HR, 1.94; 95% CI, 1.43-2.62) exhibited a higher risk of appropriate ICD therapies, whereas patients with hypertrophic cardiomyopathy (HR, 0.72; 95% CI, 0.54-0.96) and Brugada syndrome (HR, 0.25; 95% CI, 0.14-0.45) showed a lower risk. All-cause death was 13.4% at follow-up. Ischemic cardiomyopathy (HR, 3.09; 95% CI, 2.58-5.90), dilated cardiomyopathy (HR, 3.33; 95% CI, 2.18-5.10), and valvular heart disease (HR, 3.97; 95% CI, 2.25-6.99) had the worst prognoses. Delayed high-rate detection was enabled in 39.7% of patients, and single-zone programming occurred in 52.6% of primary prevention patients. Both parameters correlated with lower risk of first appropriate ICD therapy, with no excess risk of mortality. The rate of inappropriate shocks at follow-up was low (6%) and did not differ among type of ICD but was lower in SmartShock-capable devices. Conclusions Irrespective of the cause, contemporary ICD patients with heart failure-related disorders had a similar risk of ICD life-saving interventions and death. Current ICD programming recommendations still need to be implemented. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NTC01561144.
dc.identifier.doi10.1161/JAHA.120.018108
dc.identifier.essn2047-9980
dc.identifier.pmcPMC7955463
dc.identifier.pmid33356406
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955463/pdf
dc.identifier.unpaywallURLhttps://www.ahajournals.org/doi/pdf/10.1161/JAHA.120.018108
dc.identifier.urihttp://hdl.handle.net/10668/16841
dc.issue.number1
dc.journal.titleJournal of the American Heart Association
dc.journal.titleabbreviationJ Am Heart Assoc
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen de la Victoria
dc.page.numbere018108
dc.pubmedtypeJournal Article
dc.pubmedtypeObservational Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectall‐cause death
dc.subjectappropriate implantable cardioverter‐defibrillator therapy
dc.subjectimplantable cardioverter‐defibrillator
dc.subjectinappropriate shock
dc.subjectsustained ventricular arrhythmia
dc.subject.meshCohort Studies
dc.subject.meshDefibrillators, Implantable
dc.subject.meshElectric Countershock
dc.subject.meshEquipment Failure Analysis
dc.subject.meshFemale
dc.subject.meshHeart Diseases
dc.subject.meshHeart Failure
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMortality
dc.subject.meshNeeds Assessment
dc.subject.meshPreventive Health Services
dc.subject.meshRisk Assessment
dc.subject.meshSpain
dc.subject.meshSurvival Analysis
dc.subject.meshTachycardia, Ventricular
dc.titleLong-Term Outcomes Among a Nationwide Cohort of Patients Using an Implantable Cardioverter-Defibrillator: UMBRELLA Study Final Results.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7955463.pdf
Size:
1.04 MB
Format:
Adobe Portable Document Format